Mama For Health

  Introduction to Triple X Syndrome   Triple X syndrome , also known as Trisomy X or 47,XXX, is a genetic condition affecting females where an additional X chromosome is present. Typically, females have two X chromosomes, but in this case, there is an extra one, leading to a total of three X chromosomes. While the condition may not present noticeable symptoms in many cases, some females with Triple X syndrome may experience developmental delays, learning disabilities, and other health complications. The syndrome occurs in approximately 1 in 1,000 female births globally. Triple X Syndrome Market Insight and Growth Drivers   The Triple X syndrome market is primarily driven by increasing awareness, better genetic testing, and advanced diagnostic tools. Although the condition often goes undiagnosed due to mild or absent symptoms, improved screening methods, including prenatal testing, are contributing to earlier diagnosis rates. The availability of genetic counseling and support services

  Overview of DUPIXENT  DUPIXENT (dupilumab) , developed by Sanofi and Regeneron, has added another significant achievement to its portfolio by receiving the first-ever biologic approval for treating Chronic Obstructive Pulmonary Disease (COPD). DUPIXENT, already a blockbuster drug, has been a game-changer in treating various allergic and inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. With its recent approval for COPD, it marks a significant milestone in expanding the treatment landscape for one of the most challenging respiratory diseases. COPD and the Need for New Treatments   COPD is a progressive lung disease characterized by obstructed airflow, leading to breathing difficulties, chronic cough, and frequent respiratory infections. It is one of the leading causes of morbidity and mortality worldwide, affecting over 380 million people globally. Until now, treatment options for COPD have been limited to bronchodilators,